Trial Profile
Efficacy of fibrinogen/thrombin [VeraSeal] in patients undergoing vascular surgery
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 03 Nov 2015
Price :
$35
*
At a glance
- Drugs Fibrinogen/thrombin (Primary)
- Indications Surgical blood loss
- Focus Therapeutic Use
- 03 Nov 2015 New trial record
- 28 Sep 2015 According to a European Medicines Agency media release, Grifols announced the withdrawal of its MAA of VeraSeal intended to control surgical blood loss during vascular surgery.